- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
The therapy was originally co-developed by bluebird bio but following its spin-off in 2021 became part of 2seventy's portfolio.
The U.S. health regulator will not meet its Dec. 16 deadline to decide on the expanded use of Bristol Myers Squibb and partner 2seventy bio's blood cancer therapy in earlier lines of treatment as it plans to seek the advice of experts, the companies said on Monday.The U.S. Food and Drug Administration (FDA) has not yet confirmed when the advisory panel would meet, they added.The FDA in 2021...
The U.S. health regulator will not meet its Dec. 16 deadline to decide on the expanded use of Bristol Myers Squibb and partner 2seventy bio's blood cancer therapy in earlier lines of treatment as it plans to seek the advice of experts, the companies said on Monday.
The U.S. Food and Drug Administration (FDA) has not yet confirmed when the advisory panel would meet, they added.
The FDA in 2021 had approved the cell therapy Abecma as a treatment for adult patients with multiple myeloma after four or more prior therapies did not show improvement in patients.
The therapy was originally co-developed by bluebird bio but following its spin-off in 2021 became part of 2seventy's portfolio.
The latest marketing application for the cell therapy was based on data from a late-stage study that showed significant reduction in the risk of disease progression or death in patients who had received two to four prior treatments.
The FDA usually follows the recommendations of its advisers but is not obligated to do so.
Abecma faces competition from Johnson & Johnson and partner Legend Biotech's Carvykti, which was approved for the same indication last year.
The therapies belong to a class of treatments called chimeric antigen receptor T-cell therapies, or better known as CAR-T therapies, which work by harvesting a patient's own disease-fighting T-cells, genetically engineering them to seek out and attack the cancer.
Bristol Myers and 2seventy bio, however, have faced manufacturing constraints, and a month-long planned maintenance shutdown of one of Abecma's manufacturing facility in June had also negatively impacted sales.
In the third quarter, 2seventy bio's Abecma sales declined 8% to $69 million.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751